SOX2 and neoplasm: The link between antigen-specific T-cell immunity and clinical responses to PD-1 blockade in NSCLC patients suggests that the patients lacking T-cell responses against SOX2 may constitute ideal candidates for SOX2-targeting vaccines compared to those individuals with pre-existing anti-tumor immune responses who have already been benefited clinically from immune checkpoint-blocking agents.